The immune response to major gastrointestinal cancer surgery and potential implications for adjuvant immunotherapy.
Esophageal cancer
Immunotherapy
Neoadjuvant
Perioperative immunosuppression
Surgery
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
20
01
2022
revised:
11
05
2022
accepted:
26
05
2022
pubmed:
7
6
2022
medline:
22
6
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
The perioperative period theoretically is a critical time of opportunity for the progression of pre-existing tumour micrometastasis. Therefore,the timing of introducing cancer therapies including chemotherapy, radiation therapy and immunotherapies in the postoperative period is important. A thorough exploration of the perioperative immune events at a cellular level in combination with an intricate review of available clinical rials was conducted to extrapolate the effects of oncological surgery on the perioperative immune milieu.This is timely in view of the recently published Checkmate-577 trial which demonstrated significant disease-free survival in carcinoma of the gastroesophageal junction with the use of adjuvant anti-programmed cell deathprotein 1(PD-1) immunotherapy.This review focusing in particular on perioperative immunosuppression, identifies potential modifiable factors, the effects of perioperative conditioning and optimisation, the most recent trials in the curative setting for Gastrointestinal malignancies and the new treatment avenues possible in the context of the combination of immunotherapy and major oncological gastrointestinal surgery.
Identifiants
pubmed: 35662586
pii: S1040-8428(22)00153-6
doi: 10.1016/j.critrevonc.2022.103729
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103729Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.